This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignees: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp Limited, University of Michigan. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2022
Title: Chengzhe Wu: Innovator in Cancer Treatment
Introduction
Chengzhe Wu is a notable inventor based in Suzhou, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cancer treatment. His innovative work has led to the creation of a patent that holds promise for improving therapeutic options for patients.
Latest Patents
Chengzhe Wu holds a patent for "Macrocyclic spiroethers as Mcl-1 inhibitors." This patent includes compounds represented by Formula (I-A) and their pharmaceutically acceptable salts and solvates. The compounds are designed for use in treating conditions responsive to Mcl-1 inhibition, such as cancer. This advancement highlights his commitment to addressing critical health challenges through innovative solutions.
Career Highlights
Throughout his career, Chengzhe Wu has worked with reputable organizations, including Ascentage Pharma (Suzhou) Co., Ltd. and the University of Michigan. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Chengzhe Wu has collaborated with notable colleagues, including Jianyong Chen and Yunlong Zhou. These partnerships have fostered a collaborative environment that enhances the potential for innovative discoveries in cancer treatment.
Conclusion
Chengzhe Wu's contributions to the field of pharmaceuticals, particularly through his patent on Mcl-1 inhibitors, demonstrate his dedication to advancing cancer treatment. His work continues to inspire innovation and collaboration in the scientific community.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile